<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04228263</url>
  </required_header>
  <id_info>
    <org_study_id>HRP_2020</org_study_id>
    <nct_id>NCT04228263</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine and Unexplained Recurrent Miscarriage</brief_title>
  <official_title>Hydroxychloroquine for Improvement of Pregnancy Outcome in Unexplained Recurrent Miscarriage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recurrent miscarriage affects women of childbearing age worldwide. Vascular endothelial
      dysfunction and immunological impairment are associated with both recurrent miscarriage and
      preeclampsia. To date, there is no effective or optimal therapeutic approach for these
      conditions. Hydroxychloroquine has endothelial protective action via ant diabetic, lipid
      lowering, antioxidant effects or direct endothelial protection. Hydroxychloroquine is an
      antimalarial and immunomodulatory agent. In pregnancy, hydroxychloroquine is prescribed for
      inflammatory conditions associated with adverse perinatal outcomes such as systemic lupus
      erythematosus, antiphospholipid syndrome and placental inflammatory lesions such as chronic
      histiocytic intervillositis, hydroxychloroquine has therapeutic potential to improve
      placental function in pregnancies associated with heightened inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of viable fetuses at 20 weeks gestation</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Hydroxychloroquine</condition>
  <arm_group>
    <arm_group_label>hydroxychloroquine group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>hydroxychloroquine 400 mg preconceptional</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>400mg</description>
    <arm_group_label>hydroxychloroquine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>5 mg</description>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_label>hydroxychloroquine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose aspirin</intervention_name>
    <description>75 mg</description>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_label>hydroxychloroquine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women had at least 2 previous miscarriage before 20 weeks.

          -  Women trying to conceive.

          -  No anatomical or endocrine cause of recurrent pregnancy loss.

          -  Women who have given their informed consent.

          -  The negative antibody test for antiphospholipid syndrome

        Exclusion Criteria:

          -  Women who are already pregnant.

          -  Known contraindication to treatment by Hydroxychloroquine (

          -  Patients already using Hydroxychloroquine

          -  Impossible to follow-up.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Abdel-rahman Mahmoud Mohammed</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdel-rahman Mohammed, MSc</last_name>
      <phone>+201006374448</phone>
      <email>Abdoelkady4ever@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 11, 2020</study_first_submitted>
  <study_first_submitted_qc>January 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>January 11, 2020</last_update_submitted>
  <last_update_submitted_qc>January 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Abdelrahman Mahmoud Mohammed</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

